Cardio Diagnostics director receives stock options
Cardio Diagnostics Holdings, Inc. director Burton Paul Frederick reported a new stock option award.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cardio Diagnostics Holdings, Inc. director Burton Paul Frederick reported a new stock option award. On 12/31/2025, he was granted 2,306 stock options (right to buy common stock) with a conversion or exercise price of $2.71 per share. After this grant, he beneficially owns 7,259 derivative securities in the form of stock options, held in direct ownership. The filing was made on Form 4 for a single reporting person, reflecting an option grant coded as an acquisition.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 2,306 | $2.71 | $6K |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Cardio Diagnostics (CDIO) report on this Form 4?
Who is the reporting person in this Cardio Diagnostics (CDIO) Form 4 filing?
How many Cardio Diagnostics stock options does the director hold after this transaction?
What are the key terms of the stock options granted to the Cardio Diagnostics director?
Is the Cardio Diagnostics director’s ownership in these options direct or indirect?
Does this Form 4 involve non-derivative Cardio Diagnostics securities?
AI-generated analysis. How Rhea-AI works. Not financial advice.